Psychemedics Revenue Growth Rates (PMD), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Psychemedics Corporation  (PMD)
    Sector • Healthcare    Industry • Medical Laboratories
   Industry • Medical Laboratories
   Sector • Healthcare
 

PMD's Revenue Growth by Quarter and Year

Psychemedics's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

PMD Revenue (in millions $) FY 2024 FY 2023 FY 2022 FY 2021
4th Quarter December 4.39
3rd Quarter September 5.04
2nd Quarter June 4.55
1st Quarter March 5.12
FY 19.10

PMDs Annual Revenue
Psychemedics's Revenue in the fiscal year 2024 $ 19.10 millions
Psychemedics's Revenue in the fiscal year 2023 $ 21.41 millions
Psychemedics's Revenue in the fiscal year 2022 $ 25.24 millions
Psychemedics's Revenue in the fiscal year 2021 $ 24.91 millions
Psychemedics's Revenue in the fiscal year 2020 $ 21.36 millions




PMD Revenue fourth quarter 2024 Y/Y Growth Comment
Psychemedics Corporation reported decline in Revenue in the fourth quarter 2024 by -18.74% to $ 4.39 millions, from the same quarter in 2023.
The contraction in the fourth quarter 2024 Psychemedics Corporation's Revenue compares unfavorably to the Company's average Revenue growth of 2.23%.

Looking into fourth quarter 2024 results within Medical Laboratories industry 32 other companies have achieved higher Revenue growth. While Psychemedics Corporation' s Revenue fall of -18.74% ranks overall at the positon no. 3814 in the fourth quarter 2024.


PMD Revenue ( Y/Y Growth %) 2024
 2023 2022 2021
4th Quarter December -18.74 % -5.26 % -11.49 % 20.6 %
3rd Quarter September -0.98 % -21.93 % -2.25 % 29.01 %
2nd Quarter June -10.08 % -22.27 % 6.9 % 83.99 %
1st Quarter March -12.63 % -9.98 % 14.01 % -24.27 %
FY   -10.8 % -15.17 % 1.32 % -

Financial Statements
Psychemedics's fourth quarter 2024 Revenue $ 4.39 millions PMD's Income Statement
Psychemedics's fourth quarter 2023 Revenue $ 5.40 millions Quarterly PMD's Income Statement


PMD Revenue (Quarter on Quarter Growth %)

 2024
 2023 2022 2021
4th Quarter December -12.94 % 6.09 % -12.58 % -3.45 %
3rd Quarter September 10.77 % 0.59 % 0.15 % 9.52 %
2nd Quarter June -11.13 % -13.65 % 0 % 6.65 %
1st Quarter March -5.19 % 2.81 % 1.09 % 6.93 %
FY (Year on Year)   -10.8 % -15.17 % 1.32 % -


Back to PMD Growth rate Comparisons >> Back to PMD Growth rate Comparisons >>


Revenue fourth quarter 2024 Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry #33
Healthcare Sector #515
Overall #3814

Revenue Y/Y Growth Statistics
High Average Low
83.68 % 2.23 % -64.32 %
(Mar 31 2017)   (Mar 31 2021)
Revenue fourth quarter 2024 Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry #33
Healthcare Sector #515
Overall #3814
Revenue Y/Y Growth Statistics
High Average Low
83.68 % 2.23 % -64.32 %
(Mar 31 2017)   (Mar 31 2021)

Revenue by Quarter for the Fiscal Years 2021, 2022, 2023, 2024

Psychemedics's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
56.13 % 0.5 % -56.03 %
(Sep 30 2020)  


PMD's IV. Quarter Q/Q Revenue Comment
In the IV. Quarter 2024 Psychemedics Corporation disclosed drop in Revenue from the third quarter by -12.94% to $ 4.39 millions, from $ 5.04 millions achived in the previous reporting period.

Although periodic circumstance commonly energize IV. Quarter 2024 Revenue, this plainly could not be substantial to rescue Medical Laboratories's company achievement, Most analysts pointed out.

Within Medical Laboratories industry 29 other companies have achieved higher Revenue quarter on quarter growth. While Psychemedics's Revenue growth quarter on quarter, overall rank is 3588.


Revenue Q/Q Growth Company Ranking
Within: No.
Medical Laboratories Industry #30
Healthcare Sector #528
Overall #3588
Revenue Q/Q Growth Company Ranking
Within: No.
Medical Laboratories Industry #30
Healthcare Sector #528
Overall #3588
Revenue Q/Q Growth Statistics
High Average Low
56.13 % 0.5 % -56.03 %
(Sep 30 2020)  


PMD's IV. Quarter Q/Q Revenue Comment
In the IV. Quarter 2024 Psychemedics Corporation disclosed drop in Revenue from the third quarter by -12.94% to $ 4.39 millions, from $ 5.04 millions achived in the previous reporting period.

Although periodic circumstance commonly energize IV. Quarter 2024 Revenue, this plainly could not be substantial to rescue Medical Laboratories's company achievement, Most analysts pointed out.

Within Medical Laboratories industry 29 other companies have achieved higher Revenue quarter on quarter growth. While Psychemedics's Revenue growth quarter on quarter, overall rank is 3588.


Psychemedics's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Dec 31 2024)		 12 Months Ending
(Sep 30 2024)		 12 Months Ending
(Jun 30 2024)		 12 Months Ending
(Mar 31 2024)		 12 Months Ending
(Dec 31 2023)
Cumulative Revenue 12 Months Ending $ 19.10 $ 20.12 $ 20.17 $ 20.68 $ 21.41
Y / Y Revenue Growth (TTM) -10.8 % -7.35 % -12.83 % -15.92 % -15.16 %
Year on Year Revenue Growth Overall Ranking # 3482 # 2974 # 2292 # 1680 # 1690
Seqeuential Revenue Change (TTM) -5.05 % -0.26 % -2.45 % -3.44 % -1.38 %
Seq. Revenue Growth (TTM) Overall Ranking # 2744 # 2114 # 2042 # 1576 # 2006


Cumulative Revenue growth Comment
Psychemedics's cumulative 12 months Revenue continue to decline, but on the faster rate at -10.8% year on year, at Dec 31 2024 compare to the -7.35% decrease at Sep 30 2024. If the Psychemedics's fiscal year would end at Dec 31 2024, annual Revenue would be $19 millions.

In the Healthcare sector 463 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 2974 to 3482.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry # 22
Healthcare Sector # 464
Overall # 3482

Revenue TTM Y/Y Growth Statistics
High Average Low
58.15 %
 -0.03 %
-44.8 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 22
Sector # 415
S&P 500 # 2744
Cumulative Revenue growth Comment
Psychemedics's cumulative 12 months Revenue continue to decline, but on the faster rate at -10.8% year on year, at Dec 31 2024 compare to the -7.35% decrease at Sep 30 2024. If the Psychemedics's fiscal year would end at Dec 31 2024, annual Revenue would be $19 millions.

In the Healthcare sector 463 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 2974 to 3482.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry # 22
Healthcare Sector # 464
Overall # 3482

Revenue TTM Y/Y Growth Statistics
High Average Low
58.15 %
-0.03 %
-44.8 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 22
Sector # 415
S&P 500 # 2744




Other Revenue Growth
Medical Laboratories Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
PMD's Revenue Growth Ratio versus Medical Laboratories Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue decline for the quarter ending Dec 31 2024 within Healthcare SectorY/Y Change %Revenue for the quarter ending Dec 31 2024
Adapthealth Corp -0.19%$ -0.185 millions
Bioaffinity Technologies Inc -0.26%$ -0.260 millions
Organon and Co -0.38%$ -0.375 millions
Royalty Pharma Plc-0.41%$ -0.407 millions
Carlisle Companies Incorporated-0.41%$ -0.408 millions
Silo Pharma Inc-0.41%$ -0.409 millions
Shl Telemedicine Ltd-0.52%$ -0.519 millions
Cytek Biosciences Inc -0.59%$ -0.586 millions
Kronos Bio Inc -0.70%$ -0.700 millions
Koninklijke Philips Nv-0.81%$ -0.815 millions
Enhabit Inc -0.92%$ -0.921 millions
Charles River Laboratories International inc -1.08%$ -1.078 millions
Elanco Animal Health Incorporated-1.45%$ -1.449 millions
Illumina Inc -1.60%$ -1.604 millions
Perrigo Company Plc-1.62%$ -1.616 millions
Fonar Corporation-1.72%$ -1.717 millions
Quipt Home Medical Corp -1.90%$ -1.905 millions
Bio rad Laboratories Inc -1.91%$ -1.910 millions
Surmodics Inc -2.06%$ -2.062 millions
Avantor Inc -2.10%$ -2.101 millions
Petvivo Holdings Inc -2.11%$ -2.111 millions
Iridex Corp-2.15%$ -2.153 millions
Assertio Holdings inc -2.43%$ -2.431 millions
Apyx Medical Corp-2.58%$ -2.578 millions
Bioxcel Therapeutics Inc -2.66%$ -2.660 millions
Zynex inc -2.66%$ -2.665 millions
Nrc Health-2.88%$ -2.879 millions
Teladoc Health Inc -3.03%$ -3.033 millions
Orchestra Biomed Holdings Inc -3.44%$ -3.435 millions
Xenetic Biosciences Inc -3.45%$ -3.449 millions


About Psychemedics Revenue Growth Rates (PMD), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Psychemedics Corp (CIK 806517).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001171843-25-001658
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Psychemedics Corp’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.